217 related articles for article (PubMed ID: 30194340)
21. The SP1-12LOX axis promotes chemoresistance and metastasis of ovarian cancer.
Zhang Q; Yan G; Lei J; Chen Y; Wang T; Gong J; Zhou Y; Zhao H; Chen H; Zhou Y; Wu L; Zhang J; Zhang X; Wang J; Li Y
Mol Med; 2020 May; 26(1):39. PubMed ID: 32375633
[TBL] [Abstract][Full Text] [Related]
22. Caveolin-1 mediates chemoresistance in cisplatin-resistant ovarian cancer cells by targeting apoptosis through the Notch-1/Akt/NF-κB pathway.
Zou W; Ma X; Hua W; Chen B; Cai G
Oncol Rep; 2015 Dec; 34(6):3256-63. PubMed ID: 26503358
[TBL] [Abstract][Full Text] [Related]
23. Lentivirus-Mediated RNAi silencing targeting ERCC1 reverses cisplatin resistance in cisplatin-resistant ovarian carcinoma cell line.
Du P; Zhang X; Liu H; Chen L
DNA Cell Biol; 2015 Jul; 34(7):497-502. PubMed ID: 25941922
[TBL] [Abstract][Full Text] [Related]
24. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
25. Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer.
Tian H; Yan L; Xiao-Fei L; Hai-Yan S; Juan C; Shan K
Clin Epigenetics; 2019 Oct; 11(1):153. PubMed ID: 31666131
[TBL] [Abstract][Full Text] [Related]
26. Noscapine Increases the Sensitivity of Drug-Resistant Ovarian Cancer Cell Line SKOV3/DDP to Cisplatin by Regulating Cell Cycle and Activating Apoptotic Pathways.
Shen W; Liang B; Yin J; Li X; Cheng J
Cell Biochem Biophys; 2015 May; 72(1):203-13. PubMed ID: 25510462
[TBL] [Abstract][Full Text] [Related]
27. [Potential role of ezrin and its related microRNA in ovarian cancer invasion and metastasis].
Li J; Liang SH; Lu X
Zhonghua Fu Chan Ke Za Zhi; 2010 Oct; 45(10):787-92. PubMed ID: 21176563
[TBL] [Abstract][Full Text] [Related]
28. TM4SF1 is a potential target for anti-invasion and metastasis in ovarian cancer.
Gao C; Yao H; Liu H; Feng Y; Yang Z
BMC Cancer; 2019 Mar; 19(1):237. PubMed ID: 30876464
[TBL] [Abstract][Full Text] [Related]
29. HOTAIR is a potential target for the treatment of cisplatin‑resistant ovarian cancer.
Wang Y; Wang H; Song T; Zou Y; Jiang J; Fang L; Li P
Mol Med Rep; 2015 Aug; 12(2):2211-6. PubMed ID: 25824616
[TBL] [Abstract][Full Text] [Related]
30. HOXB4 promotes the malignant progression of ovarian cancer via DHDDS.
Li N; Gou JH; Xiong J; You JJ; Li ZY
BMC Cancer; 2020 Mar; 20(1):222. PubMed ID: 32178630
[TBL] [Abstract][Full Text] [Related]
31. XIAP associated factor 1 (XAF1) represses expression of X-linked inhibitor of apoptosis protein (XIAP) and regulates invasion, cell cycle, apoptosis, and cisplatin sensitivity of ovarian carcinoma cells.
Zhao WJ; Deng BY; Wang XM; Miao Y; Wang JN
Asian Pac J Cancer Prev; 2015; 16(6):2453-8. PubMed ID: 25824780
[TBL] [Abstract][Full Text] [Related]
32. ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells.
Xu Y; Gao W; Zhang Y; Wu S; Liu Y; Deng X; Xie L; Yang J; Yu H; Su J; Sun L
Int J Oncol; 2018 Sep; 53(3):1055-1068. PubMed ID: 30015875
[TBL] [Abstract][Full Text] [Related]
33. Suppression of human ovarian carcinoma metastasis by the metastasis-suppressor gene, BRMS1.
Zhang S; Lin QD; DI W
Int J Gynecol Cancer; 2006; 16(2):522-31. PubMed ID: 16681721
[TBL] [Abstract][Full Text] [Related]
34. Paclitaxel and SN-38 overcome cisplatin resistance of ovarian cancer cell lines by down-regulating the influx and efflux system of cisplatin.
Komuro Y; Udagawa Y; Susumu N; Aoki D; Kubota T; Nozawa S
Jpn J Cancer Res; 2001 Nov; 92(11):1242-50. PubMed ID: 11714450
[TBL] [Abstract][Full Text] [Related]
35. Effect of down-regulated transcriptional repressor ZEB1 on the epithelial-mesenchymal transition of ovarian cancer cells.
Chen D; Wang J; Zhang Y; Chen J; Yang C; Cao W; Zhang H; Liu Y; Dou J
Int J Gynecol Cancer; 2013 Oct; 23(8):1357-66. PubMed ID: 24257549
[TBL] [Abstract][Full Text] [Related]
36. miR‑210‑3p regulates cell growth and affects cisplatin sensitivity in human ovarian cancer cells via targeting E2F3.
Jin Y; Wei J; Xu S; Guan F; Yin L; Zhu H
Mol Med Rep; 2019 Jun; 19(6):4946-4954. PubMed ID: 30957179
[TBL] [Abstract][Full Text] [Related]
37. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.
Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J
Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707
[TBL] [Abstract][Full Text] [Related]
38. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
[TBL] [Abstract][Full Text] [Related]
39. miR-100 resensitizes resistant epithelial ovarian cancer to cisplatin.
Guo P; Xiong X; Zhang S; Peng D
Oncol Rep; 2016 Dec; 36(6):3552-3558. PubMed ID: 27748936
[TBL] [Abstract][Full Text] [Related]
40. EGFR Blockade Reverses Cisplatin Resistance in Human Epithelial Ovarian Cancer Cells.
Poursheikhani A; Yousefi H; Tavakoli-Bazzaz J; Seyed H G
Iran Biomed J; 2020 Nov; 24(6):370-8. PubMed ID: 32660222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]